67Ga-citrate distribution in solid hepatoma 22

The intracellular distribution of 67Ga was studied in solid hepatoma 22 implanted in C3Ha/6 mice and in normal liver tissue from the same animals at different time intervals. The tissues were fractionated according to differential centrifugation principles, and subcellular fractions were isolated consecutively. The enzyme activities and the accumulation of 67Ga were determined in each fraction. The subcellular distribution of 67Ga in the tumor tissue was different compared with normal liver; in tumor it was found mainly in the nuclear fraction and this distribution was independent of time, but in normal liver the accumulation was mainly in the mitochondrial fraction, this was time-dependent and the maximal uptake was found 48 h after 67Ga administration.

Diffuse-object holograms in dichromated gelatin

A two-step method has been developed to obtain a diffuse-object hologram with high efficiency and low noise. In the first step a silver-halide gelatin hologram with high signal-to-noise ratio is obtained. In the second one, this hologram is copied onto dichromated gelatin using a partially coherent source. Results are compared with those obtained directly in dichromated gelatin using coherent light from an argon laser.

113mIn-tripolyphosphate: a new radiopharmaceutical for bone scanning

A compound was synthetized, which by X-Ray diffraction studies proved to be hexahydrated sodium tripolyphosphate. By means of in vitro procedures, it was demonstrated that this compound was able to complex trivalent cations, and that 113mIn could be completely incorporated to it. In vivo studies in rats, and scans performed with this new radiopharmaceutical in humans showed its highly selective accumulation in metastasic bone tumors.

The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans

The study was aimed at evaluating the effect of pyridinolcarbamate in patients with atherosclerosis obliterans of the lower limbs. A single intravenous administration of the drug did not induce changes in resting blood flow, but elicited a significant decline in capillary filtration rate. In a double-blind cross-over trial patients reported a significant prolongation of walking distance after 6 months of pyridinolcarbamate treatment. Sensation of cold in the lower limbs was not affected. Pyridinolcarbamate did not influence peak values of blood flow through the calf but they appeared significantly earlier. No significant changes were seen at the evaluation of the elevation and dependency test and performance using tiptoeing test. Likewise the findings of systolic pressure in the lower limbs, pulse wave morphology, and claudication distance on treadmill did not confirm a therapeutic effect of pyridinolcarbamate.